1. Home
  2. RPRX vs TLK Comparison

RPRX vs TLK Comparison

Compare RPRX & TLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • TLK
  • Stock Information
  • Founded
  • RPRX 1996
  • TLK 1884
  • Country
  • RPRX United States
  • TLK Indonesia
  • Employees
  • RPRX N/A
  • TLK N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • TLK Telecommunications Equipment
  • Sector
  • RPRX Health Care
  • TLK Telecommunications
  • Exchange
  • RPRX Nasdaq
  • TLK Nasdaq
  • Market Cap
  • RPRX 14.0B
  • TLK 16.2B
  • IPO Year
  • RPRX 2020
  • TLK 1995
  • Fundamental
  • Price
  • RPRX $33.82
  • TLK $15.23
  • Analyst Decision
  • RPRX Strong Buy
  • TLK
  • Analyst Count
  • RPRX 5
  • TLK 0
  • Target Price
  • RPRX $41.60
  • TLK N/A
  • AVG Volume (30 Days)
  • RPRX 4.6M
  • TLK 690.6K
  • Earning Date
  • RPRX 02-11-2025
  • TLK 04-16-2025
  • Dividend Yield
  • RPRX 2.60%
  • TLK 6.97%
  • EPS Growth
  • RPRX N/A
  • TLK N/A
  • EPS
  • RPRX 1.91
  • TLK 0.02
  • Revenue
  • RPRX $2,263,576,000.00
  • TLK $9,920,511,850.00
  • Revenue This Year
  • RPRX $29.18
  • TLK $3.31
  • Revenue Next Year
  • RPRX $9.99
  • TLK $3.20
  • P/E Ratio
  • RPRX $17.69
  • TLK $10.58
  • Revenue Growth
  • RPRX N/A
  • TLK 0.35
  • 52 Week Low
  • RPRX $24.05
  • TLK $14.16
  • 52 Week High
  • RPRX $34.16
  • TLK $26.37
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 80.55
  • TLK 41.36
  • Support Level
  • RPRX $32.28
  • TLK $15.95
  • Resistance Level
  • RPRX $34.20
  • TLK $16.29
  • Average True Range (ATR)
  • RPRX 0.71
  • TLK 0.31
  • MACD
  • RPRX 0.02
  • TLK 0.04
  • Stochastic Oscillator
  • RPRX 89.40
  • TLK 44.77

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About TLK PT Telekomunikasi Indonesia Tbk

PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. The company is focusing on dividing business into 3 Digital Business Domains namely, digital connectivity, digital platform, and digital services. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services.

Share on Social Networks: